Eisai projects 42.5B yen global revenue for LEQEMBI in FY2024 amid pathway expansion (OTCMKTS:ESAIY)

Eisai projects 42.5B yen global revenue for LEQEMBI in FY2024 amid pathway expansion (OTCMKTS:ESAIY)

Earnings Call Insights: Eisai Co., Ltd. (OTCPK:ESALF) Q3 2024Management ViewCEO Haruo Naito highlighted a 9% year-on-year revenue increase to 601.2 billion...

Leqembi IV monthly maintenance dosing approved by FDA

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease. The decision follows a supplemental application from Eisai, which is codeveloping Leqembi with Biogen, based on the modeling of data from the Phase 2 Study 201 (NCT01767311) and the Phase 3 Clarity AD study (NCT03887455), and their long-term extension studies, showing that once-monthly dosing can…